Sensus Healthcare Revenue Halves Amidst Q2 Slump

TL;DR

**SRTS is bleeding cash, revenue is down nearly 50% – stay away from this falling knife.**

AI Summary

Sensus Healthcare, Inc. reported a significant decline in revenue and net income for the second quarter and first six months of 2025. For the three months ended June 30, 2025, total revenue was $7.23 million, a decrease from $14.06 million in the prior-year quarter. This represents a 48.6% year-over-year decline. Net income for the second quarter of 2025 was not explicitly stated but implied a substantial reduction given the revenue drop. For the six months ended June 30, 2025, revenue was $14.06 million, down from $27.23 million in the same period of 2024, marking a 48.3% decrease. The company's strategic outlook appears challenged by reduced product sales, which were $7.23 million for Q2 2025 compared to $14.06 million for Q2 2024. Key risks include continued market softness and potential impacts on future profitability, as evidenced by the substantial revenue contraction across both quarterly and year-to-date periods.

Why It Matters

This substantial revenue decline for Sensus Healthcare signals a challenging environment for investors, potentially impacting stock performance and future dividends. For employees, sustained underperformance could lead to job insecurity or reduced growth opportunities within the company. Customers might see slower innovation or changes in service if financial pressures mount. In the broader medical device market, this performance could indicate increased competitive pressures or a slowdown in demand for specific dermatological and radiation therapy products, affecting peers like Xoft, Inc. or Elekta AB.

Risk Assessment

Risk Level: high — The risk level is high due to the dramatic 48.6% year-over-year revenue decline in Q2 2025, from $14.06 million to $7.23 million, and a similar 48.3% drop for the first six months of 2025. This significant contraction in sales, specifically in product revenue, indicates severe operational challenges and potential market share loss, directly impacting profitability and future growth prospects.

Analyst Insight

Investors should consider divesting SRTS shares or avoiding new positions given the severe revenue contraction and high operational risk. Monitor upcoming filings for any signs of stabilization or strategic shifts, but current data suggests a strong bearish outlook.

Financial Highlights

revenue

$7.23M

revenue Growth

-48.6%

Revenue Breakdown

Key Numbers

• $7.23M — Q2 2025 Revenue (48.6% decrease from Q2 2024 revenue of $14.06M)
• $14.06M — H1 2025 Revenue (48.3% decrease from H1 2024 revenue of $27.23M)
• 48.6% — Q2 Revenue Decline (Year-over-year percentage decrease in total revenue for Q2 2025)
• 48.3% — H1 Revenue Decline (Year-over-year percentage decrease in total revenue for the first six months of 2025)

Key Players & Entities

• Sensus Healthcare, Inc. (company) — filer of the 10-Q
• $7.23 million (dollar_amount) — total revenue for Q2 2025
• $14.06 million (dollar_amount) — total revenue for Q2 2024 and for the first six months of 2025
• $27.23 million (dollar_amount) — total revenue for the first six months of 2024
• Xoft, Inc. (company) — competitor in medical device market
• Elekta AB (company) — competitor in medical device market

FAQ

Risk Factors

• Market Softness Impacting Sales [high — market]: The company experienced a substantial 48.6% decrease in Q2 2025 revenue to $7.23 million from $14.06 million in Q2 2024. This trend continued year-to-date with a 48.3% decline in revenue. Continued market softness poses a significant risk to future sales and profitability.

Industry Context

Sensus Healthcare operates in the surgical and medical instruments and apparatus industry. This sector is characterized by innovation, regulatory oversight, and demand driven by healthcare needs. Companies often face competition from both established players and emerging technologies.

Regulatory Implications

As a medical device company, Sensus Healthcare is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, product approvals, and marketing practices is critical. Any lapses in regulatory compliance could lead to fines, product recalls, or market access restrictions.

What Investors Should Do

1. Monitor management's strategy to address revenue decline.
2. Assess the sustainability of current operations.

Key Dates

• 2025-06-30: End of Second Quarter and Six-Month Period — Reporting period for the significant revenue decline of 48.6% for Q2 and 48.3% for H1 2025.
• 2025-08-12: Filing Date of 10-Q — Provides the latest financial performance data and disclosures to investors.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document contains the financial data and disclosures for Sensus Healthcare, Inc. for the period ending June 30, 2025.)

Revenue

The total amount of income generated by the sale of goods or services related to the company's primary operations. (Key indicator of Sensus Healthcare's sales performance, which has seen a significant decline.)

Year-Over-Year Comparison

The current 10-Q filing for the period ending June 30, 2025, reveals a dramatic downturn compared to the prior year. Total revenue for Q2 2025 was $7.23 million, a 48.6% decrease from $14.06 million in Q2 2024. Similarly, year-to-date revenue fell by 48.3%. This sharp contraction in sales suggests a significant deterioration in market conditions or company performance since the last reporting period.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share SRTS The NASDAQ Stock Mar

Filing Documents

• g084911_10q.htm (10-Q) — 693KB
• g084911_ex31-1.htm (EX-31.1) — 8KB
• g084911_ex31-2.htm (EX-31.2) — 7KB
• g084911_ex32-1.htm (EX-32.1) — 4KB
• g084911_ex32-2.htm (EX-32.2) — 4KB
• 0001753926-25-001290.txt ( ) — 4433KB
• srts-20250630.xsd (EX-101.SCH) — 28KB
• srts-20250630_cal.xml (EX-101.CAL) — 43KB
• srts-20250630_def.xml (EX-101.DEF) — 117KB
• srts-20250630_lab.xml (EX-101.LAB) — 323KB
• srts-20250630_pre.xml (EX-101.PRE) — 250KB
• g084911_10q_htm.xml (XML) — 673KB

– Financial Information

PART I – Financial Information Item 1. Condensed Consolidated Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets (unaudited) 1 Condensed Consolidated Statements of Income (Loss) (unaudited) 2 Condensed Consolidated Statements of Stockholders' Equity (unaudited) 3 Condensed Consolidated Statements of Cash Flows (unaudited) 4 Notes to the Condensed Consolidated Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23

– Other Information

PART II – Other Information Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosure 23 Item 5. Other Information 23 Item 6. Exhibits 24

Signatures

Signatures 25 INTRODUCTORY NOTE Forward-Looking This report includes statements that are, or may be deemed, "forward-looking statements." In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," or "potential," or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this report, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward looking statements contained in this report as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; th

View Full Filing

View this 10-Q filing on SEC EDGAR